AUSTRALIAN drug development
company Avexa has dropped its
HIV program after it failed to
secure a manufacturer to market its
apricitabine antiviral therapy for the
treatment of drug resistant HIV.
CEO Julian Chick has also
advised that he will assume
responsibility for apricitabine’s
commercial failure by stepping
down from his position from the
end of this month.
Avexa’s shares have plummeted
by 75% to just three cents.
The company has appointed a
corporate advisory firm to conduct
a strategic review “with the primary
focus of uncovering a transaction
that will be value accretive for our
shareholders,” said chairman
Nathan Drona.The above article was sent to subscribers in Pharmacy Daily's issue from 11 May 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 May 10
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.